GlassScriptPhysician profile
Benjamin Orie Herzberg
NPI 1861873275
$24,236.38
in general payments reported to CMS, 2019-2025
16 companies · $18K in 2025
The $18K reported for 2025 was more than what 87% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $106 · 2023: $970 · 2024: $4,752 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $751 · Travel and Lodging: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,707.50 |
| Food and Beverage | $751.26 |
| Travel and Lodging | $671.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $9,133.82 | 2024-2025 | |
| Janssen Global Services, LLC | $7,050.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,875.00 | 2024 | |
| Janssen Research & Development, LLC | $2,520.00 | 2025 | |
| Amgen INC. | $1,452.71 | 2023-2025 | Lumakras, Blincyto |
| Abbvie INC. | $600.00 | 2025 | |
| Ambu INC. | $125.00 | 2023 | |
| Genentech USA, INC. | $114.49 | 2024-2025 | |
| Mirati Therapeutics, INC. | $109.34 | 2023 | Krazati |
| G1 Therapeutics, INC. | $86.72 | 2023 | Cosela |
| Eli Lilly and Company | $63.00 | 2025 | |
| Atricure, INC. | $55.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $50.77 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Herzberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.